Skip to main content

Table 2 Acceptability ratings for aspects of the BPaL (Nix) regimen and the individualized treatment regimena

From: Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

  Overall (N = 182) Indonesia Kyrgyzstan Nigeria
ITR BPaL ITR BPaL ITR BPaL ITR BPaL
Baseline assessment and monitoring of treatment efficacy Total 144 144 46 45 51 50 47 49
Acceptable 106 (74%) 127 (88%) 35 (76%) 38 (84%) 43 (84%) 47 (94%) 28 (60%) 42 (86%)
Neutral 26 (18%) 14 (10%) 7 (15%) 7 (16%) 6 (12%) 2 (4%) 13 (28%) 5 (10%)
Unacceptable 12 (8%) 3 (2%) 4 (9%) 0 (0%) 2 (4%) 1 (2%) 6 (13%) 2 (4%)
Treatment safety monitoring Total 141 140 44 43 52 52 45 45
Acceptable 108 (77%) 115 (84%) 39 (89%) 31 (72%) 42 (81%) 45 (87%) 27 (60%) 39 (87%)
Neutral 19 (14%) 21 (15%) 2 (5%) 9 (21%) 5 (10%) 7 (14%) 12 (27%) 5 (11%)
Unacceptable 14 (10%) 4 (3%) 3 (7%) 3 (7%) 5 (10%) 0 (0%) 6 (13%) 1 (2%)
Patient friendliness Total 136 133 43 43 39 39 54 51
Acceptable 61 (45%) 124 (93%) 20 (47%) 37 (86%) 23 (59%) 37 (95%) 18 (33%) 50 (98%)
Neutral 33 (24%) 6 (5%) 11 (26%) 5 (12%) 9 (23%) 1 (3%) 13 (24%) 0 (0%)
Unacceptable 42 (31%) 3 (2%) 12 (28%) 1 (2%) 7 (18%) 1 (3%) 23 (43%) 1 (2%)
Programmatic aspects Total 141 132 44 42 41 41 56 53
Acceptable 85 (60%) 110 (83%) 30 (68%) 29 (69%) 28 (68%) 33 (89%) 27 (48%) 48 (91%)
Neutral 32 (23%) 19 (14%) 8 (18%) 11 (26%) 10 (24%) 3 (8%) 14 (25%) 5 (9%)
Unacceptable 24 (17%) 3 (2%) 6 (14%) 2 (5%) 3 (7%) 1 (3%) 15 (27%) 0 (0%)
Patient support Total 146 144 41 41 48 48 57 54
Acceptable 100 (69%) 122 (85%) 29 (71%) 33 (81%) 34 (71%) 45 (92%) 37 (65%) 44 (82%)
Neutral 27 (19%) 19 (13%) 9 (22%) 8 (20%) 6 (13%) 3 (6%) 12 (21%) 8 (15%)
Unacceptable 19 (13%) 3 (2%) 3 (7%) 0 (0%) 8 (17%) 1 (2%) 8 (14%) 2 (4%)
Human resources Total 153 153 42 42 49 51 62 60
Acceptable 90 (59%) 121 (79%) 29 (69%) 27 (64%) 29 (59%) 46 (90%) 32 (52%) 48 (80%)
Neutral 43 (28%) 26 (17%) 9 (21%) 13 (31%) 14 (29%) 4 (8%) 20 (32%) 9 (15%)
Unacceptable 20 (13%) 6 (4%) 4 (10%) 2 (5%) 6 (12%) 1 (2%) 10 (16%) 3 (5%)
PSCM Total 79 74 25 25 28 26 26 24
Acceptable 53 (67%) 59 (80%) 18 (72%) 14 (56%) 20 (71%) 23 (92%) 15 (58%) 22 (92%)
Neutral 14 (18%) 13 (18%) 4 (16%) 10 (40%) 5 (18%) 2 (8%) 5 (19%) 1 (4%)
Unacceptable 12 (15%) 2 (3%) 3 (12%) 1 (4%) 3 (11%) 1 (0%) 6 (23%) 1 (4%)
  1. a Since certain topics of the acceptability matrix were only collected for certain stakeholder groups and optional or not required for others (Table 1), only missing values for “mandatory” topics for the respective stakeholder were considered “true missing” values. Answers were excluded if the question was not a topic for the respective stakeholder
  2. BPaL bedaquiline & pretomanid & linezolid, ITR Individualized Treatment Regimen, PSCM procurement and supply chain management